Hypothesis

Co-transplanting iPSC-derived dopaminergic neurons (DA) with iPSC-derived microglia-like cells (iMG) will improve functional integration and behavioral recovery in Parkinsonian rodents by supplying activity-dependent BDNF and modulating the inflammatory milieu.

Rationale

• Preclinical work shows iPSC-DA grafts survive variably and often fail to form robust circuits [2]
• iPSC-derived microglia can phagocytose debris and release neurotrophic factors, including BDNF, in response to neuronal activity [3]
• BDNF signaling promotes dopaminergic neuron maturation, axon outgrowth, and synaptic plasticity, which are critical for circuit restoration.
• Allogeneic off-the-shelf iPSC lines are now in clinical trials, indicating manufacturing scalability [1]

Experimental Design

1. Groups (n=10 per group):
   • Vehicle control
   • DA neurons alone
   • DA + iMG (1:1 ratio)
   • DA + iMG + BDNF neutralizing antibody
   • DA + iMG + P2X7 receptor antagonist (to block activity-dependent BDNF release)
2. Model: 6-OHDA lesioned rats, immunosuppressed to allow xenograft survival.
3. Readouts (at 4, 8, 12 weeks):
   • Graft survival (TH+ immunostaining)
   • Dopaminergic fiber density in striatum
   • Microglial activation state (Iba1, CD68)
   • BDNF levels in graft microenvironment (ELISA)
   • Behavioral assays: amphetamine-induced rotation, cylinder test, pole test.
4. Analysis: Compare DA+ iMG to DA alone; test whether BDNF blockade abrogates benefits.

Predicted Outcomes

• DA+ iMG grafts will show ~30% higher TH+ cell survival and ~2-fold increase in striatal TH+ fiber density vs DA alone.
• Behavioral improvement will be significant in DA+ iMG group, correlating with graft BDNF levels.
• BDNF neutralization or P2X7 antagonism will reduce survival and behavioral gains to DA-alone levels, confirming the mechanistic link.
• iMG will display a ramified, anti-inflammatory phenotype (low CD68, high Arg1) in the graft zone.

Potential Pitfalls & Mitigations

• Xenogeneic immune rejection: use immunosuppressants (tacrolimus) and HLA-matched iPSC lines; monitor for graft inflammation.
• Variability in iMG differentiation: standardize protocol with CSF1 and IL34 supplementation; validate microglia markers before transplantation.
• Off-target effects of BDNF antibody: include isotype control and verify BDNF specificity via western blot.

If the hypothesis holds, it would provide a mechanistic rationale for incorporating immunomodulatory cell types into iPSC-based neurodegenerative therapies, moving beyond pure cell replacement toward a supportive niche that enhances functional integration.